Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle weakness and degeneration. It is caused by mutations in the dystrophin gene, leading to the absence of the dystrophin protein in muscle cells. Research in the field of Duchenne muscular dystrophy focuses on developing treatments and therapies to improve muscle function and quality of life for individuals affected by the condition. This includes gene therapy, stem cell therapy, and pharmacological interventions to address muscle degeneration and weakness. Additionally, researchers are investigating ways to improve the diagnosis and early detection of DMD, as well as understanding the underlying mechanisms of the disease to identify potential targets for intervention.